On Thursday, Abbott announced it had received FDA emergency use authorization for the first rapid antigen COVID-19 nasal swab test that does not require any additional testing equipment. The test called BinaxNOW is fast, affordable and can detect coronavirus infections on a massive scale. On the heels of that approval, President Trump has announced a major purchase of 150 million rapid coronavirus tests from Abbott. For more on how this news could change the fight against the coronavirus, we spoke to Dr. John Hackett, divisional vice president of applied research and technology for Abbott's diagnostics business.